All In Biotech

Drug Trial Radar · NCT04198766

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Multicohort, Phase 1/2 Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab in Subjects With Locally Advanced or Metastatic Solid Tumors

Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 340 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

340

Planned (sponsor's estimate)

Start

Dec 10, 2019

Primary completion

Jul 2033

Study completion Jul 2033

Sponsor

Lead sponsor
Inhibrx Biosciences, IncIndustry
Sponsor type
Industry
Collaborators
Merck Sharp & Dohme LLC
First posted
Dec 13, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combination with the anti-PD-1 checkpoint inhibitor (CPI) pembrolizumab (Keytruda®). KEYTRUDA is a registered trademark of Merck Sharp \& Dohme LLC, a subsidiary of Merck \& Co., Inc., Rahway, NJ, USA.

Conditions

  • Solid Tumor
  • Non-Small Cell Lung Cancer
  • Head and Neck Cancer
  • Melanoma
  • Gastric Cancer
  • Renal Cell Carcinoma
  • Urothelial Carcinoma
  • Resectable Non-Small-Cell Lung Cancer

Interventions

  • INBRX-106 - Hexavalent OX40 agonist antibodyDrug

    The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4).

  • pembrolizumab 200 mgDrug

    pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.

  • pembrolizumab 400 mgDrug

    pembrolizumab 400 mg by IV infusion given on Day 1 of alternating 21-day cycles (every 6 weeks)

  • Carboplatin AUC-5Drug

    carboplatin AUC-5 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycles 1-4. Cohort F8, carboplatin AUC-5 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycle 2-4.

  • Carboplatin AUC-6Drug

    carboplatin AUC-6 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycles 1-4

  • Pemetrexed 500 mg/m2Drug

    pemetrexed 500 mg/m2 by IV infusion given on Day 1 of each 21-Day cycle for up to 35 cycles. In Cohort F8, pemetrexed 500 mg/m2 by IV infusion given on Day 1 of each 21-Day cycle of cycles 1-4.

  • Cisplatin 75mg/m2Drug

    cisplatin 75mg/m2 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycles 1-4

  • Paclitaxel 200mg/m2Drug

    paclitaxel 200mg/m2 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycles 1-4

  • Nab paclitaxel 100mg/m2Drug

    Nab paclitaxel 100mg/m2 by intravenous (IV) infusion, given on Days 1, 8 and 15 of each 21-day cycle of cycles 1-4

  • Gemcitabine (1000 mg/m2)Drug

    Gemcitabine 1000 mg/m2 given by intravenous (IV) infusion on Days 1 and 8 of each 21-day cycle of cycles 1-4

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Frequency of adverse events of INBRX-106 as single agent and in combination with pembrolizumabTime frame: ~2 years
  2. Severity of adverse events of INBRX-106 as single agent and in combination with pembrolizumabTime frame: ~2 years
  3. MTD and/or RP2D of INBRX-106 as single agent and in combination with pembrolizumabTime frame: ~2 years
  4. Antitumor activity of INBRX-106 in combination with pembrolizumab in expansion cohortsTime frame: ~2 years
  5. Frequency and severity of adverse events of INBRX-106 in combination with pembrolizumab and chemotherapy in adults with locally advanced or metastatic NSCLC or resectable Stage II, IIIA or IIIB (T3-4N2) NSCLCTime frame: ~2 years
  6. To assess the antitumor activity of INBRX-106 in combination with pembrolizumab and platinum doublet chemotherapy as neoadjuvant/adjuvant therapy in adult subjects with NSCLC. (Cohort F8)Time frame: ~2 years

Locations

60 sites in 4 countries. Site status is shown where the registry gives one.

  • City of Hope

    Duarte, California · Active not recruiting

  • Oncura Health

    Glendale, California · Recruiting

  • UC San Diego Health - Moores Cancer Center

    La Jolla, California · Not yet recruiting

  • California Research Institute

    Los Angeles, California · Recruiting

  • University of Southern California Norris Comprehensive Cancer Center

    Los Angeles, California · Not yet recruiting

  • Valkyrie Clinical Trials

    Los Angeles, California · Recruiting

  • Valkyrie Clinical Trials

    Murrieta, California · Recruiting

  • Providence Medical Foundation

    Santa Rosa, California · Recruiting

  • Valkyrie Clinical Trials - Colorado

    Lakewood, Colorado · Not yet recruiting

  • Clermont Oncology Center

    Clermont, Florida · Recruiting

  • Mid Florida Hematology and Oncology Center

    Orange City, Florida · Recruiting

  • Winship Cancer Institute - Emory University

    Atlanta, Georgia · Active not recruiting

  • University of Illinois Cancer Center

    Chicago, Illinois · Not yet recruiting

  • The University of Chicago Medical Center

    Chicago, Illinois · Active not recruiting

  • University of Iowa

    Iowa City, Iowa · Recruiting

  • Norton Cancer Institute

    Louisville, Kentucky · Recruiting

  • Barbara Ann Karmanos Cancer Institute

    Detroit, Michigan · Completed

  • Henry Ford Cancer Institute

    Detroit, Michigan · Recruiting

  • START Midwest

    Grand Rapids, Michigan · Active not recruiting

  • HealthPartners Cancer Research Center

    Saint Louis Park, Minnesota · Active not recruiting

  • HealthPartners Cancer Research Center (Regions Hospital)

    Saint Paul, Minnesota · Completed

  • Washington University in St. Louis School of Medicine

    St Louis, Missouri · Not yet recruiting

  • Intermountain Health Cancer Centers of Montana

    Billings, Montana · Completed

  • Nebraska Cancer Specialists - Grand Island

    Grand Island, Nebraska · Not yet recruiting

  • Nebraska Cancer Specialists

    Omaha, Nebraska · Recruiting

  • MD Anderson Cancer Center at Cooper

    Camden, New Jersey · Not yet recruiting

  • Montefiore Medical Center

    The Bronx, New York · Active not recruiting

  • Cleveland Clinic

    Cleveland, Ohio · Active not recruiting

  • Providence Portland Medical Center

    Portland, Oregon · Active not recruiting

  • Lehigh Valley Health Network

    Allentown, Pennsylvania · Not yet recruiting

  • University of Tennessee Health Science Center

    Knoxville, Tennessee · Not yet recruiting

  • Vanderbilt University School of Medicine

    Nashville, Tennessee · Active not recruiting

  • Sarah Cannon Research Institute at Mary Crowley

    Dallas, Texas · Completed

  • Renovatio Clinical - El Paso

    El Paso, Texas · Completed

  • NEXT Oncology

    San Antonio, Texas · Completed

  • Renovatio Clinical

    The Woodlands, Texas · Completed

  • The University of Texas Health Science Center at Tyler

    Tyler, Texas · Recruiting

  • Virginia Cancer Specialists

    Fairfax, Virginia · Completed

  • Froedtert Hospital and the Medical College of Wisconsin

    Milwaukee, Wisconsin · Recruiting

  • Curie Oncology

    Singapore, Singapore · Completed

Showing 40 of 60 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.